Biotech startups are built on venture capital. Track funding rounds ...
2024年11月21日 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.
Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The top biopharma conferences in 2025 | BioPharma Dive
2024年10月1日 · American Association of Cancer Research Annual Meeting. April 25 - 30, 2025 Chicago. While the American Society of Clinical Oncology’s meeting often gets billed as the field’s largest conference, AACR has become an equally major gathering for cancer research, particularly earlier-stage findings on new drug mechanisms of action or treatment modalities.
Verdiva starts up with $411M and a portfolio of obesity drugs …
2025年1月9日 · Dive Brief: A year after negotiating a $1 billion sale to GSK, a group of former Aiolos Bio executives are starting a well-funded new drugmaker promising to deliver better obesity treatments.; Verdiva Bio announced its launch Thursday alongside $411 million in Series A financing, the third-largest funding round since the beginning of 2022 among the top venture capital firms tracked by ...
Drug patents protect pharma profits. Track when they’ll expire.
2024年5月8日 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.
A Vertex partner — and potential rival — secures $100M to …
2024年12月18日 · SiteOne has a complicated relationship with Vertex. Its lead program also regulates NaV1.8, meaning the companies may one day be competitors. Yet they are also working together on a different non-opioid pain drug that targets the “NaV1.7” sodium channel.
Novartis shutters MorphoSys sites, lays off staff
2024年12月19日 · Novartis agreed to acquire MorphoSys for about $2.9 billion in a February deal to gain access to pelabresib, which the German biotechnology company developed for myelofibrosis, a rare condition that causes abnormal blood cell production.. Novartis had high expectations for the drug after its success in late-stage testing alongside the …
Drugmakers are racing to find the next Wegovy. These obesity …
2024年10月10日 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
Vertex ‘ends the year in pain’ as latest non-opioid drug data ...
2024年12月19日 · Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched pain drug disappointed Wall Street.. The medication is meant to be a non-addictive alternative to opioids, and has shown in multiple clinical trials the ability to alleviate acute pain as well as a form of chronic nerve pain.
AbbVie to acquire Roche spinout Nimble in immune drug deal
2024年12月13日 · Dive Brief: AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical company said Friday.; Chief among that pipeline is an oral therapy designed to inhibit a protein called IL-23, the same target of AbbVie’s blockbuster injection Skyrizi.